Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CT texture analysis and delta radiomics in predicting R0 resection after preoperative chemotherapy in resectable pancreatic ductal adenocarcinoma.

Translational oncology·2026
Same author

Multi-omic single nuclei profiling of murine pancreas shows dynamic epigenetic heterogeneity of acinar cells.

Cell death and differentiation·2026
Same author

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Author Correction: CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages.

NPJ precision oncology·2026
Same author

Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to <i>Kras</i> <sup>G12D</sup> Inhibition in Pancreatic Cancer.

Cancer communications (London, England)·2026
Same author

Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma.

Proceedings of the National Academy of Sciences of the United States of America·2026

Related Experiment Video

Updated: May 9, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Rationale and clinical use of multitargeting anticancer agents.

Davide Melisi1, Geny Piro, Anna Tamburrino

  • 1Digestive Molecular Clinical Oncology Research Unit, Medical Oncology, Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy.

Current Opinion in Pharmacology
|July 17, 2013
PubMed
Summary

Human solid tumors exhibit genetic diversity, leading to treatment resistance. Overcoming this complex cancer requires broad, multi-targeted therapeutic strategies to address dynamic cellular subpopulations and adaptive signaling pathways.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Experiment Videos

Last Updated: May 9, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Area of Science:

  • Oncology
  • Cancer Biology
  • Translational Medicine

Background:

  • Human solid tumors are characterized by intratumor heterogeneity, comprising genetically distinct cell subpopulations.
  • This heterogeneity is dynamically modulated by selective pressures from therapeutic interventions, contributing significantly to treatment resistance.
  • Cancer complexity is further amplified by interconnected signaling pathways, compensatory mechanisms, and escape routes that promote tumor cell survival and secondary growth.

Purpose of the Study:

  • To highlight the role of tumor cell heterogeneity as a fundamental driver of cancer drug resistance.
  • To underscore the impact of complex, cross-talking signaling networks on therapeutic outcomes.
  • To advocate for the development of broad, multi-targeted therapeutic strategies for complex cancers.

Main Methods:

  • Review of existing literature on tumor heterogeneity and cancer resistance mechanisms.
  • Analysis of signaling pathway crosstalk and compensatory events in cancer progression.
  • Conceptual framework for multi-targeted therapeutic approaches.

Main Results:

  • Tumor heterogeneity and adaptive signaling are key determinants of variable drug responses.
  • Redundant and escape pathways enable cancer cells to survive and regrow under treatment.
  • Existing treatments often fail due to the dynamic and complex nature of cancer.

Conclusions:

  • Cancer's heterogeneous and dynamic nature necessitates a paradigm shift in treatment strategies.
  • Broad, multi-targeted therapies are essential to effectively combat complex solid tumors.
  • Addressing intratumor heterogeneity and adaptive resistance is critical for improving patient outcomes.